Please assess the completion status of the following clinical trial:

Trial Title: Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of ≥18 years.~2. Definite diagnosis of AS according to the modified New York criteria.~3. History of an inadequate response to ≥2 NSAIDs taken for at least 2 weeks each or NSAIDs intolerance/contraindication.~4. Active disease as defined by a BASDAI value of ≥4 at screening despite concomitant treatment with an NSAID or without NSAIDs in case of intolerance/contraindication.~5. Able and willing to give a written informed consent and comply with the requirements of the study protocol.~6. If female: either not of child-bearing potential (menopausal since 1 year or surgically sterile) or is willing and able to practice a reliable method of contraception.~7. If male: either not of child-bearing potential (surgically sterilized, e.g. vasectomy) or is willing and able to practice a reliable method of contraception.~8. If on NSAIDs: the dose must be stable for at least 2 weeks prior to baseline.~9. If on oral steroids: the dose must not exceed 10 mg (prednisolone equivalent) per day and must be stable for at least 4 weeks prior to baseline.~10. If on methotrexate: the dose must not exceed 25 mg per week and must be stable for at least 4 weeks prior to baseline, must be stable for 4 weeks prior to baseline.~11. If on analgesics: the dose must be stable for at least 2 weeks prior to baseline.~Exclusion Criteria:~1. The female subject is pregnant or lactating.~2. Patients with other chronic inflammatory articular disease or systemic autoimmune disease.~3. History of inadequate response to previous anti-tumor necrosis factor (TNF) α therapy.~4. Previous treatment with biologics other than TNF α blockers.~5. Treatment with any other investigational drug within 4 weeks of 5 half-life of the drug (whichever is longer) prior to baseline.~6. Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks with a standard cholestyramine wash-out).~7. Treatment with intravenous, intramuscular or intraarticular/periarticular steroids within 4 weeks prior to screening.~8. Any active current infection, a history of recurrent clinically significant infection, infections requiring treatment with antibiotics within 4 weeks prior to baseline.~9. Current clinical signs and symptoms suggestive for tuberculosis.~10. Positive interferon gamma release assay (IGRA) test at screening and/or abnormal chest x-ray (performed at screening or within 3 months prior to screening) suggestive for past or present tuberculosis (positive x-ray). Patients with a positive IGRA test but negative chest x-ray and without clinical symptoms suggestive for tuberculosis may participate in the study after initiation of standard prophylactic antimycobacterial treatment.~11. Chronic infection with hepatitis B or C, history of human immunodeficiency virus infection.~12. Primary or secondary immunodeficiency.~13. Actual malignancies or history of malignancies with curative treatment within 5 years prior to screening, except successfully treated non-metastatic squamous-cell or basal-cell carcinoma or carcinoma in situ of the cervix.~14. Evidence of severe uncontrolled gastrointestinal, hepatic, renal, pulmonary, cardiovascular, nervous or endocrine disorders.~15. Any other conditions making the patient unsuitable in the opinion of the investigator for the participation in the current study.~16. Patients with a history of a severe psychiatric illness, which might interfere with the patient's ability to understand the requirements of the study and assessment.~17. Diagnosis of fibromyalgia.~18. Alcohol abuse or illegal drug consume in the last 12 months.~19. Vaccination with a live vaccine within 12 weeks prior to baseline.~20. Known hypersensitivity to any component of the study medication.~21. Clinically significant laboratory abnormalities~22. Patients who are institutionalised due to regulatory or juridical order.~23. Patients with contraindications for the magnetic resonance imaging (MRI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ustekinumab (Type: EXPERIMENTAL): Ustekinumab 90 mg subcutaneously at week 0, 4 and 16

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete